Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
D407960-1ml | 1ml | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $277.90 |
α-adrenergic receptor Selective Inhibitors | Agonists | Antagonists
Specifications & Purity | Moligand™, 10mM in DMSO |
---|---|
Biochemical and Physiological Mechanisms | Dexmedetomidine is a sedative medication used by intensive care units and anesthetists. |
Storage Temp | Store at -80°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Product Description | Information Dexmedetomidine is a sedative medication used by intensive care units and anesthetists. Dexmedetomidine has a relatively high ratio of α2/α1-activity (1620:1 as compared with 220:1 for clonidine) and, therefore, is considered a full agonist of the α2 receptor. This may result in more potent effects of sedation without unwanted cardiovascular effects from α1 receptor activation. The 2-h half-life of dexmedetomidine is nearly 4-fold shorter than that of clonidine, which increases the likelihood that a continuous infusion of dexmedetomidine might be useful for sedation. Dexmedetomidine also has minimum alveolar anesthetic concentration (MAC)-sparing properties, but its use as an anesthetic adjuvant has been complicated by persistent hypotension that has mandated IV fluid administration and vasopressor administration. In addition, its use in large doses is complicated by hypertension from α2 receptor-mediated vascular constriction. In vivo
cell lines: Concentrations: Incubation Time: Powder Purity:≥99% |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Canonical SMILES | CC(C1=CN=C[NH]1)C2=CC=CC(=C2C)C |
---|---|
Molecular Weight | 200.28 |
Enter Lot Number to search for COA:
Solubility | Solubility (25°C) In vitro DMSO: 33 mg/mL (198.53 mM); |
---|
1. Gao Yang, Kang Kai, Liu Yan-song, Li Na-na, Han Qiu-yuan, Liu Hai-tao, Kong Wei-lan, Zhang Xing, Huang Rui, Yang Zhen-yu, Qi Zhi-dong, Zheng Jun-bo, Li Ming, Wang Hong-liang, Li Jia-yu, Liu Rui-jin, Wang Si-cong, Zhang Wei-hua, Zhao Ming-yan, Yu Kai-jiang. (2021) Mechanisms of Renal-Splenic Axis Involvement in Acute Kidney Injury Mediated by the α7nAChR-NF-κB Signaling Pathway. INFLAMMATION, 44 (2): (746-757). [PMID:33141376] [10.1007/s10753-020-01374-y] |
1. Gao Yang, Kang Kai, Liu Yan-song, Li Na-na, Han Qiu-yuan, Liu Hai-tao, Kong Wei-lan, Zhang Xing, Huang Rui, Yang Zhen-yu, Qi Zhi-dong, Zheng Jun-bo, Li Ming, Wang Hong-liang, Li Jia-yu, Liu Rui-jin, Wang Si-cong, Zhang Wei-hua, Zhao Ming-yan, Yu Kai-jiang. (2021) Mechanisms of Renal-Splenic Axis Involvement in Acute Kidney Injury Mediated by the α7nAChR-NF-κB Signaling Pathway. INFLAMMATION, 44 (2): (746-757). [PMID:33141376] [10.1007/s10753-020-01374-y] |